GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
| 
                               
                            
                                
                                                                Synonyms: Azstarys® (serdexmethylphenidate + dexmethylphenidate) | KP-484 | KP484
                                 
                                                         
                            
                            
                            
                                 
                                
                                serdexmethylphenidate is an approved drug (FDA (2021)) 
                                                        
                                                    
                                Compound class: 
                                                            Synthetic organic
                                 
                                
                                    
                                        Comment: Serdexmethylphenidate (KP484) is a prodrug that is a slow-release derivative of dexmethylphenidate (d-MPH).
                                    
                                 
                            
                            
                          
                                
                                    
                                
                          
                                   
                                   
                                  
                                    
                                    
                                     | 
                                    
                                        
                                         
  | 
                                    
                                
                                |||||||||||||||||||||||||||||||||||
| No information available. | 
Summary of Clinical Use ![]()  | 
                                                        
| Serdexmethylphenidate in combination with dexmethylphenidate was approved by the FDA in March 2021 as a treatment for ADHD in children ≥6 years old. The orally administered fixed dose combination was known as KP415 during the development process. Serdexmethylphenidate has a delayed onset and prolonged duration of effects, so acts as a long-acting psychostimulant, whilst dexmethylphenidate provides a more rapid onset of action. | 
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References | 
| NCT03460652 | KP415 Open-Label Safety Study in Children (6-12 Years of Age) With ADHD | Phase 3 Interventional | KemPharm, Inc. | ||